Paul Balmer

Paul Balmer

Auto-generated profile, based on publicly available information

Paul Balmer

Vaccine Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in Expert Review of Vaccines
Verified
Journal Article
Open access
JFJamie Findlow
Jamie Findlow
JLJay Lucidarme
Jay Lucidarme
MTMuhamed-Kheir Taha
Muhamed-Kheir Taha
CBCynthia Burman
Cynthia Burman
PBPaul Balmer
Paul Balmer
Recombinant surface protein meningococcal serogroup B (MenB) vaccines are available but with different antigen compositions, leading to differences between vaccines in their immunogenicity and like...

3 June 2022 in Expert Review of Vaccines
Verified
Journal Article
Open access
JFJamie Findlow
Jamie Findlow
RBRay Borrow
Ray Borrow
DSDavid S. Stephens
David S. Stephens
PLPaul Liberator
Paul Liberator
AAAnnaliesa S. Anderson
Annaliesa S. Anderson
LJLuis Jodar
Luis Jodar
The two currently licensed surface protein non-capsular meningococcal serogroup B (MenB) vaccines both have the purpose of providing broad coverage against diverse MenB strains. However, the differ...

22 February 2021 in Postgraduate Medicine
Verified
Journal Article
Open access
LHLiping Huang
Liping Huang
SSSonya J. Snedecor
Sonya J. Snedecor
PBPaul Balmer
Paul Balmer
ASAmit Srivastava
Amit Srivastava
Globally, 5 serogroups (A, B, C, W, and Y) cause the majority of invasive meningococcal disease (IMD). Vaccines targeting these serogroups are currently part of the US adolescent immunization platf...


5 December 2024 in Epidemiology and Infection
Verified
Journal Article
Open access
MHMyint Tin Tin Htar
Myint Tin Tin Htar
JFJamie Findlow
Jamie Findlow
PBPaul Balmer
Paul Balmer
DSDavid Swerdlow
David Swerdlow
Serogroup epidemiology of invasive meningococcal disease (IMD) is constantly evolving, varying by time and location. Surveillance reports have indicated a rise in meningococcal serogroup Y (MenY) in some regions in recent years. This systematic literature review explores the evolving epidemiology of MenY IMD globally based on review of recent articles and national surveillance reports published between 1 January 2010 and 25 March 2021. Generally, MenY incidence was low (<0.2/100,000) across all ages in most countries. The reported incidence was more frequent among infants, adolescents, and those aged ≥65 years. More than 10% of all IMD cases were MenY in some locations and time periods. Implementation of vaccination evolved over time as the rise in MenY IMD percentage occurred. Cases decreased in countries with quadrivalent vaccine programs (e.g., United Kingdom, the Netherlands, United States, and Australia), whereas the MenY burden increased and made up a large proportion of cases in areas without vaccine programs. Continuous monitoring of epidemiologic changes of IMD is essential to establish MenY burden and for implementation of prevention strategies.

30 January 2025 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
SKSusanna Koski
Susanna Koski
Federico Martinón-TorresFederico Martinón-Torres
Federico Martinón-Torres
MRMika Rämet
Mika Rämet
LZLefteris Zolotas
Lefteris Zolotas
RNRyan Newton
Ryan Newton
JBJohannes Beeslaar
Johannes Beeslaar
Introduction Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix®) in infants were evaluated. Methods In this phase 3b, open-label, single-arm study, healthy 3-month-old infants received a single Nimenrix dose followed by a booster at age 12 months (1 + 1 series). Functional antibodies before and 1 month after each vaccination were evaluated with serum bactericidal antibody assays using rabbit (rSBA) or human (hSBA) complement for each A/C/W/Y serogroup. Primary endpoints were rSBA seroprotection (titers ≥ 1:8) rates and geometric mean titers (GMTs); supportive secondary endpoints included hSBA seroprotection (titers ≥ 1:4) rates and GMTs. Local reactions and systemic events occurring within 7 days, adverse events (AEs), serious AEs, and newly diagnosed chronic medical conditions following vaccination were assessed. Results Overall, 147 and 143 participants received the primary and booster Nimenrix doses, respectively. rSBA seroprotection rates across serogroups were 82.3–91.1% at 1 month after the primary dose and increased to 100% at 1 month after the booster. rSBA GMTs were considerably higher after the booster (1299.5‒2714.1) than after the primary dose (54.7‒202.4). In hSBA evaluations performed as supportive to rSBA evaluations, seroprotection rates increased from 38.8 to 95.5% after the primary dose to 100% after the booster, with corresponding GMT increases (8.8‒149.8 to 1208.4‒7299.6). Local reactions and most systemic events were mild to moderate in severity; no new safety concerns were identified. Conclusion Nimenrix given at ages 3 and 12 months had a favorable safety profile and elicited protective immune responses and robust anamnestic booster responses across A/C/W/Y serogroups. These results provide important support for this alternative Nimenrix 1 + 1 immunization schedule for infants < 6 months, allowing flexibility in infant meningococcal immunization. Trial Registration ClinicalTrials.gov, NCT04819113.